Biocon: Company Statement
Biocon (BIOCON) filed a disclosure titled "Company Statement". The company is valued at about ₹52,721 crore.
What happened
Biocon (BIOCON) filed a disclosure with the exchanges on 26 October 2026 at 08:27 AM titled "Company Statement".
Company snapshot
Biocon is a mid-cap company in the Healthcare sector, with a market value of about ₹52,721 crore.
The stock last traded at ₹323.5, against a 52-week range of ₹318.4–₹447.2 (27.6% below the high).
Before this filing the shares had moved −17.1% over the month and −25.4% over three months. Average daily turnover over the last 20 sessions was about ₹93.13 crore.
Promoters held 44.68% at the end of Q1 FY27. Foreign institutions owned 8.14% and domestic institutions 23.38%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 3,942 | 31.4 | 0.26 |
| Q2 FY26 | 4,296 | 84.5 | 0.66 |
| Q3 FY26 | 4,173 | 143.8 | 1.08 |
| Q4 FY26 | 4,517 | 125.9 | 0.79 |
| Q1 FY27 | 4,336 | 141.1 | 0.87 |
What history shows
BCEIE's records show 3 previous approval filings from the company since May 2026.
After those filings, the stock fell 0.9% on average the next trading day and was up 1.3% on average after five days (3 filings with price data).
Across 114 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +1.0% over five days; 52% of them rose the next day.
Market-wide, 1,519 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 14 Oct 2026 | Company Statement | +0.3% | — |
| 25 Sept 2026 | 'Company Statement'. | −3.1% | — |
| 18 Aug 2026 | Company Statement | +0.2% | +1.3% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Biocon Ltd. Share Price Today - Biocon Ltd. Stock Price Live NSE/BSE
- Biocon Secures Pebrilzo Launch Dates; Shares Fall 0.94%
- Biocon settles Perjeta biosimilar dispute with Roche; rollout to start from Q1 CY27
- Natural Biocon (India) Ltd. Estimates – BSE:NATURAL
- Biocon Settles Patent Dispute With Genentech; Shares Down
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.